Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-CIK and anti-PD-1 in refractory solid tumors
NCT02886897Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2016
- Primary completion
- Sep 2019
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), bladder cancer and 4 more, sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)bladder cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02886897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886897.